1. Home
  2. Analysis
  3. Trifluridine
  4. Oxervate

Trifluridine and Oxervate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Trifluridine (trifluridine) and Oxervate (cenegermin-bkbj). Common drug interactions include eye pain among females and eye pain among males.

The phase IV clinical study analyzes what interactions people have when they take Trifluridine and Oxervate. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Trifluridine?

Trifluridine has active ingredients of trifluridine. eHealthMe is studying from 387 Trifluridine users. Check the latest studies of Trifluridine.

What is Oxervate?

Oxervate has active ingredients of cenegermin-bkbj. eHealthMe is studying from 7,219 Oxervate users. Check the latest studies of Oxervate.

On Jul, 17, 2026

17 people who take Trifluridine and Oxervate together, and have interactions are studied.

Trifluridine and Oxervate drug interactions.

What are the common drug interactions of Trifluridine and Oxervate, by gender? *:

female:

  1. Eye pain
  2. Eye irritation
  3. Vision blurred
  4. Disease progression
  5. Eye discharge
  6. Eye pruritus (eye itching)
  7. Eyelid pain
  8. Herpes zoster
  9. Abdominal discomfort
  10. Influenza

male:

  1. Eye pain
  2. Ocular hyperaemia (an abnormally large amount of blood in eye)
  3. Eye infection viral
  4. Cough
  5. Dry eye (lack of adequate tears)
  6. Eye irritation
  7. Eye swelling
  8. Hypersensitivity
  9. Impaired driving ability
  10. Nasopharyngitis (inflammation of the nasopharynx)

What are the common drug interactions of Trifluridine and Oxervate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Eye pain
  2. Dry eye (lack of adequate tears)

30-39:

n/a

40-49:

n/a

50-59:

  1. Eye infection viral
  2. Eye pain

60+:

  1. Herpes zoster
  2. Eye discharge
  3. Eye irritation
  4. Eye pain
  5. Intraocular pressure increased
  6. Pterygium (benign growth of the conjunctiva)
  7. Surgery

What are the existing conditions these people have? *

  1. Neurotrophic Keratopathy (decreased corneal sensitivity and poor corneal healing): 13 people, 76.47%
  2. Keratitis (eye's cornea, the front part of the eye, becomes inflamed): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Trifluridine and Oxervate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Trifluridine and Oxervate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Trifluridine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Oxervate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Trifluridine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Oxervate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on trifluridine and cenegermin-bkbj (the active ingredients of Trifluridine and Oxervate, respectively), and Trifluridine and Oxervate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.